These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2194485)

  • 1. Paradoxes of pertussis toxin.
    Wardlaw AC
    Zentralbl Bakteriol; 1990 May; 273(1):1-4. PubMed ID: 2194485
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization.
    Hausman SZ; Burns DL
    Infect Immun; 2000 Jun; 68(6):3763-7. PubMed ID: 10816544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin.
    Rappuoli R; Pizza M; De Magistris MT; Podda A; Bugnoli M; Manetti R; Nencioni L
    Immunobiology; 1992 Feb; 184(2-3):230-9. PubMed ID: 1587545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards third-generation whooping cough vaccines.
    Rappuoli R; Pizza M; Podda A; De Magistris MT; Nencioni L
    Trends Biotechnol; 1991 Jul; 9(7):232-8. PubMed ID: 1370047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of whooping cough bacterium may reduce vaccine effectiveness.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1430. PubMed ID: 25396233
    [No Abstract]   [Full Text] [Related]  

  • 6. The advent of recombinant pertussis vaccines.
    Burnette WN
    Biotechnology (N Y); 1990 Nov; 8(11):1002-5. PubMed ID: 1366927
    [No Abstract]   [Full Text] [Related]  

  • 7. Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response.
    Rappuoli R; Pizza M; Covacci A; Bartoloni A; Nencioni L; Podda A; De Magistris MT
    FEMS Microbiol Immunol; 1992 Oct; 5(4):161-70. PubMed ID: 1384602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
    Hegerle N; Guiso N
    Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of Bordetella pertussis.
    He Q
    Pediatr Infect Dis J; 2016 Aug; 35(8):915-7. PubMed ID: 27213264
    [No Abstract]   [Full Text] [Related]  

  • 10. Foreword. Pertussis vaccines.
    Poolman JT
    Expert Rev Vaccines; 2014 Sep; 13(9):1067-9. PubMed ID: 25115214
    [No Abstract]   [Full Text] [Related]  

  • 11. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.
    Taranger J; Trollfors B; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    J Infect Dis; 2000 Mar; 181(3):1010-3. PubMed ID: 10720524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum IgG antibody response to pertussis toxin in persons for whom pertussis vaccination failed depends upon the number of antigens in the vaccine.
    Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):560-1. PubMed ID: 10194078
    [No Abstract]   [Full Text] [Related]  

  • 13. Pertussis infection and vaccination induces Th1 cells.
    Brady MT; Mahon BP; Mills KH
    Immunol Today; 1998 Nov; 19(11):534. PubMed ID: 9818551
    [No Abstract]   [Full Text] [Related]  

  • 14. Secretory IgA against pertussis toxin and surface structures of Bordetella pertussis in saliva of children with culture proven pertussis.
    Frühwirth M; Wolf H; Heininger H; Guggenbichler JP; Stehr E
    Adv Exp Med Biol; 1995; 371B():777-83. PubMed ID: 7502896
    [No Abstract]   [Full Text] [Related]  

  • 15. Emergence of Bordetella holmesii as a Causative Agent of Whooping Cough, Barcelona, Spain.
    Mir-Cros A; Codina G; Martín-Gómez MT; Fàbrega A; Martínez X; Jané M; Van Esso D; Cornejo T; Rodrigo C; Campins M; Pumarola T; González-López JJ
    Emerg Infect Dis; 2017 Nov; 23(11):1856-1859. PubMed ID: 29052540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertussis (whooping cough) toxin and Bordetella pertussis whole-cell antibody levels in a healthy New Zealand population.
    Lau RC
    N Z Med J; 1989 Oct; 102(878):560-2. PubMed ID: 2554227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of pertactin in pertussis vaccines: the jury is still out.
    Desauziers E; Danve B; Decker MD; Veitch K
    J Infect Dis; 2004 Apr; 189(7):1332-3; author reply 1333-5. PubMed ID: 15031804
    [No Abstract]   [Full Text] [Related]  

  • 19. Protective effect of acellular pertussis vaccines.
    Blennow M; Hedenskog S; Granström M
    Eur J Clin Microbiol Infect Dis; 1988 Jun; 7(3):381-3. PubMed ID: 3137039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathogenetic significance of Bordetella pertussis toxin].
    Finger H
    Immun Infekt; 1985 Apr; 13(2):47-9. PubMed ID: 2860059
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.